A Study to Evaluate the Effectiveness, Tolerability and Safety of Laquinimod

Launched by TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. · Jul 5, 2006

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Willing and able to give written informed consent
• • 2. Confirmed MS diagnosis as defined by the McDonald criteria
• • 3. R-R MS disease course.
• • 4. At least one gadolinium-enhanced lesion on screening MRI
• • 5. Women of child-bearing potential must practice a reliable method of birth control.
• • 6. Must understand the requirements of the study and agree to comply with the study protocol.
• Exclusion Criteria:
• • 1. Subjects who suffer from any form of progressive MS.
• • 2. Any condition which the investigator feels may interfere with participation in the study.
• • 3. Subjects with a clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation,
• • 4. Subjects who received any investigational medication, immunosuppressives or cytotoxic agents within 6 months prior to screening
• • 5. Previous treatment with immunomodulators within two months prior to screening